Market LIVE
Published markets; coverage varies by country
Product profile · United States

VANFLYTA

 ·  Patent Litigation & Settlement History ↓

IngredientQUIZARTINIB DIHYDROCHLORIDE
Application typeNDA
Application216993
Product001
Dosage formTABLET
RouteORAL
StrengthEQ 17.7MG BASE
Approval date2023-07-20
Marketing statusPrescription
Status event—
ApplicantDAIICHI SANKYO INC
Product source

Current GenericRadar decision

Year2030
SelectionDEEP_REVIEW
ReviewFINAL
Anchor typeREGULATORY_EXCLUSIVITY
Anchor date2030-07-20
Patent anchor2029-08-15
Exclusivity anchor2030-07-20
Protection date2033-09-30
First Final ANDA—
Status event—

GNR judgment: DEEP_REVIEW. Reference year: 2030. Anchor type: REGULATORY_EXCLUSIVITY. Patent anchor: 2029-08-15. Exclusivity anchor: 2030-07-20. Anchor date: 2030-07-20. Patent tail: yes. Exclusivity tail: no. Review status: FINAL. Historical detailed rationale is retained in the evidence snapshot; this is a structured English summary, not a literal translation.

Patent estate

PatentEffective dateOfficial listingTRUE_DSDS gradeClaim classification / basisPTEPEDFamily
81293742027-03-16U U-3661NYU
English description not available.
———
81293742027-03-16ORANGE_BOOK U-3661NYU
English description not available.
———
85578102027-03-16DP —NNDP
English description not available.
———
85578102027-03-16ORANGE_BOOK —NNDP
English description not available.
———
88837832027-03-16DS —NNOTHER
English description not available.
———
88837832027-03-16ORANGE_BOOK —NNOTHER
English description not available.
———
95858922027-03-16U U-3661NNOTHER
English description not available.
———
95858922027-03-16ORANGE_BOOK U-3661NNOTHER
English description not available.
———
78206572028-09-26DS —YNTRUE_DS
English description not available.
———
78206572028-09-26ORANGE_BOOK —YNTRUE_DS
English description not available.
———
79685432029-08-15DP/U U-3661NYU
English description not available.
———
79685432029-08-15ORANGE_BOOK U-3661NYU
English description not available.
———
88657102029-08-15DP —NNDP
English description not available.
———
88657102029-08-15ORANGE_BOOK —NNDP
English description not available.
———
88362182030-03-23U U-3661NNU
English description not available.
———
88362182030-03-23ORANGE_BOOK U-3661NNU
English description not available.
———
95550402030-05-14U U-3661NNU
English description not available.
———
95550402030-05-14ORANGE_BOOK U-3661NNU
English description not available.
———
83576902031-02-26U U-3661NNU
English description not available.
———
83576902031-02-26ORANGE_BOOK U-3661NNU
English description not available.
———
96755492033-09-30DP —NNDP
English description not available.
———
96755492033-09-30ORANGE_BOOK —NNDP
English description not available.
———

Regulatory exclusivity

CodeStart dateEnd dateScopeEntire productAll indicationsFull coverage dateCombinationSource
NCE2023-07-202028-07-20English description not available.YY2028-07-20—Source
NCE2023-07-202028-07-20English description not available.YY2028-07-20
ODE-437
Full coverage date: 2028-07-20
Source
ODE-4372023-07-202030-07-20English description not available.YY2030-07-20—Source
ODE-4372023-07-202030-07-20English description not available.YY2030-07-20
ODE-437
Full coverage date: 2030-07-20
Source

2026-10-10 · CURRENT_SOURCE_RECORDS_FOUND · Historical coverage: NOT_COMPLETE

Generic approval evidence

Application / productEventFinal dateTentative dateApplicantAuthorized genericExact mappingSource
No generic approval facts are linked to this product.

Market Entry Information

API filings, authorized generics and linked regulatory milestones.

API Master Files & Certifications 0 records

Ingredient-level registrations from linked public manufacturer portfolios. A filing does not establish supply to this finished product. DMFs are not FDA approvals.

APIHolder / manufacturerHolder countryFiling typeNumberStatusFiled dateAvailable for referenceSourceLast verified
No master-file or certification records are linked through public manufacturer portfolios.

Authorized Generics 0 records

Authorized generics are shown separately from independent ANDA approvals.

Application / productApplicantEvent / status First marketed Product mappingSourceLast verified
No authorized-generic records are linked to this product.

Tentative ANDA Approvals 0 records

Tentative approval is not final approval. Historical tentative approvals remain visible after a linked final approval.

Application / productApplicantEvent / status Tentative date Follow-up final approvalProduct mappingSourceLast verified
No tentative-approval records are linked to this product.

Paragraph IV Challenges 0 records

Paragraph IV challenges below are sourced from legal records separately from FDA approvals. An ANDA filing, lawsuit or settlement does not establish final approval or commercial launch.

Application / productApplicantEvent / status Certification event date Product mappingSourceLast verified
No structured Paragraph IV certification events are linked in the available approval evidence.

Final ANDA Approvals 0 records

Approval dates do not establish commercial launch. Product mapping is shown for each linked record.

Application / productApplicantEvent / status Final approval date Product mappingSourceLast verified
No final-approval records are linked to this product.
Decision evidence (14)
TypeDateRoleBasisSource
PATENT2027-03-16HISTORICAL_CONTEXTEnglish description not available.Source
PATENT2027-03-16HISTORICAL_CONTEXTEnglish description not available.Source
PATENT2027-03-16HISTORICAL_CONTEXTEnglish description not available.Source
PATENT2027-03-16HISTORICAL_CONTEXTEnglish description not available.Source
PATENT2028-09-26HISTORICAL_CONTEXTEnglish description not available.Source
PATENT2029-08-15CANONICAL_ANCHOREnglish description not available.Source
PATENT2029-08-15HISTORICAL_CONTEXTEnglish description not available.Source
PATENT2030-03-23HISTORICAL_CONTEXTEnglish description not available.Source
PATENT2030-05-14HISTORICAL_CONTEXTEnglish description not available.Source
PATENT2031-02-26FTO_TAILEnglish description not available.Source
PATENT2033-09-30FTO_TAILEnglish description not available.Source
REGULATORY_EXCLUSIVITY—REGULATORY_SCOPE_CONTEXTEnglish description not available.Source
REGULATORY_EXCLUSIVITY—CANONICAL_ANCHOREnglish description not available.Source
REGULATORY_STATUS2030-07-20CANONICAL_DECISIONEnglish description not available.Source
Independent legal-event information

Litigation & Settlement History

Settlement launch rights generally apply only to the named parties and product scope. These records do not change GenericRadar patent/exclusivity anchors or current decisions.

No litigation or settlement record currently linked to this product.